StockpollyBeta
Get App
Popularity #1,964
CLDX · NASDAQ · Biotechnology

Celldex Therapeutics (CLDX)

Develops KIT and bispecific antibodies for mast-cell-driven inflammatory diseases.

$37.95
vs last close+0.06 (+0.16%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue240231110000
Cost of revenue13011451535463010
Gross profit1−26−12−420−52−53−630−10
422140481056111011878481
Research & development353031394546535463757368
89991010111011121113
General & administrative89991010111011121113
Other expenses−1−1800−450−53−54−630−10
Operating income−41−48−41−46−52−56−63−64−74−87−84−81
34810109977667
Interest income34810109977667
Interest expense030000000000
Other non-operating income0−13−8−10−10−9−9−7−7−6−6−7
Income before tax−38−43−33−36−42−47−54−57−67−81−79−74
Net income from continuing operations−38−43−33−36−42−47−54−57−67−81−79−74
Net income−38−43−33−36−42−47−54−57−67−81−79−74
EPS, basic−$0.81−$0.83−$0.56−$0.54−$0.64−$0.71−$0.81−$0.85−$1.01−$1.23−$1.18−$0.94
EPS, diluted−$0.81−$0.83−$0.56−$0.54−$0.64−$0.71−$0.81−$0.85−$1.01−$1.23−$1.18−$0.94
Weighted average shares, basic475259666666666666676778
Weighted average shares, diluted475259666666666666676778
EBITDA−40−34−32−35−41−46−53−56−66−81−78−73
Depreciation & amortization111111111111
EBIT−41−35−33−36−42−47−54−57−67−81−79−74